Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2022 1
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Safety of RTS,S/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring study.
Haine V, Oneko M, Debois M, Ndeketa L, Agyapong PD, Boahen O, Harrison SBE, Adeniji E, Kaali S, Kayan K, Owusu-Agyei S, French N, Kariuki S, Devadiga R, Ogutu B, Ansah NA, Orsini M, Ansah PO, Maleta K, Ong'echa JM, Phiri VK, Mzanga P, Jere TM, Azongo DK, Mategula D, Orimbo J, Oduro AR, Otieno W, Kaburise MB, Ababio LO, Sifuna PM, Amoit SK, Olewe F, Oyieko JN, Achieng Oguk E, Guerra Mendoza Y, Awuni D, Sing'oei V, Onyango I, Schuerman L, Ochieng BO, Okoth GO, Nyangulu W, Cherop RY, Odera-Ojwang P, Cravcenco C, Chipatala R, Roman F, Savic M, Asante KP. Haine V, et al. Among authors: cravcenco c. Lancet Glob Health. 2025 Jun;13(6):e995-e1005. doi: 10.1016/S2214-109X(25)00096-8. Epub 2025 Apr 24. Lancet Glob Health. 2025. PMID: 40288377 Free article. Clinical Trial.
Sustained efficacy of the RTS,S/AS01E malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial.
Osei-Tutu L, Kariuki SK, Lee CK, Fabre R, Bii DK, Adjei S, Oneko M, Attobrah Sarfo MA, Ockenhouse CF, Schuerman L, Buabeng PBY, Bakari A, Atieno C, Kotoh-Mortty MF, Otieno K, Ntiamoah Y, Sang T, Bollaerts A, Westercamp N, Ansong D, Agbenyega T, Samuels AM, Ofori-Anyinam O; RTS,S study group. Osei-Tutu L, et al. Lancet Glob Health. 2025 Oct;13(10):e1723-e1736. doi: 10.1016/S2214-109X(25)00272-4. Lancet Glob Health. 2025. PMID: 40975080 Free article. Clinical Trial.
Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial.
Samuels AM, Ansong D, Kariuki SK, Adjei S, Bollaerts A, Ockenhouse C, Westercamp N, Lee CK, Schuerman L, Bii DK, Osei-Tutu L, Oneko M, Lievens M, Attobrah Sarfo MA, Atieno C, Morelle D, Bakari A, Sang T, Jongert E, Kotoh-Mortty MF, Otieno K, Roman F, Buabeng PBY, Ntiamoah Y, Ofori-Anyinam O, Agbenyega T; RTS,S study group. Samuels AM, et al. Lancet Infect Dis. 2022 Sep;22(9):1329-1342. doi: 10.1016/S1473-3099(22)00273-0. Epub 2022 Jun 23. Lancet Infect Dis. 2022. PMID: 35753316 Free PMC article. Clinical Trial.
Incidence rates of malaria, meningitis, and mortality in children younger than 5 years: a prospective cohort study in Ghana and Kenya before the roll-out of the RTS,S/AS01E malaria vaccine from 2016 to 2022.
Asante KP, Bozonnat MC, Savic M, Owusu-Agyei S, Kaali S, Otieno W, Boahen O, Tivura M, Otieno L, Agyapong PD, Ansah PO, Sing'oei V, Oyieko J, Adeniji E, Ansah NA, Harrison SBE, Oguk E, Dosoo D, Schuerman L, Kaburise MB, Awuni DA, Kayan K, Cravcenco C, Roman F, Haine V. Asante KP, et al. Among authors: cravcenco c. Lancet Glob Health. 2025 May;13(5):e859-e869. doi: 10.1016/S2214-109X(25)00022-1. Lancet Glob Health. 2025. PMID: 40288396 Free article.